Tim Clackson explains how IDRX-42 has been designed to eliminate resistance mutations that the current standard of care cannot handle,...

Madeleine gives her take on data from Caribou, Summit, Daiichi Sankyo, GSK, Abbvie, and more.

John Oyler discusses the company's marketed BTK and PD-1 therapies, and highlights a handful of programs and targets in the pipeline like...

Aron Knickerbocker describes the benefits of focusing on the CD-25 binding portion of IL-2 and discusses some data presented at ASCO. He...

Terry Rosen describes data presented at ASCO for TIGIT in upper GI cancers, adenosine in late state colorectal cancer, and non-ASCO data...

Global Head of Oncology Ken Keller and Chief Operating Officer Hiroyuki Okuzawa describe the significance of today's data and also...

Dan Paterson gives background on the rolling submission the company started this week in a type of ovarian cancer, with his thoughts on...

Jeb Keiper describes the HKP1 pathway and why he believes his company's expertise in precision engineering and machine learning has...

V.P. of Clinical Operations Jack West gives his interpretation of the announcement that Summit's partner Akeso made in China that it beat...

Bahija Jallal and David Berman go over Immunocore's PRAME data in cutaneous melanoma and explain why they believe that the disease...

Nadim Ahmed describes #ASCO24 data from today for CLN-619 and zipalertinib, and discusses taking a CD19/CD3 into the clinic for lupus.

Paul Rennert talks about the first four patients who have been dosed in Aleta's clinical trial, as well as previewing targets such as...

From McCormick Place, Jacob Plieth previews key data from Merus, Summit, Iovance, Caribou, AstraZeneca, GSK, Gilead, and more.

Tadaaki Taniguchi covers some of the work Astellas is doing with modalities like antibody-drug conjugates, T-cell engagers, and protein degr

From a pre-ASCO event in Chicago, John Flavin describes how Portal invests in startups while giving them fully equipped lab space to work...

Laura Chico discusses the biotech pullback of late, and comments on Biogen, Aerovate, Viridian, and Ovid.

Tien Lee describes how TAS2R is a bitter taste receptor that naturally activates gut hormones and gut-brain signaling and can be used to dam

Brian Lortie describes how Blackstone has launched the company and the multiple advantages this relationship brings, why TSLP, and the...

Co-Founder and CEO Taylor Schreiber describes the bi-specific fusion protein construct he is co-inventor of and why he believes it is...